EEElizabeth Devon Eldridge-Smith

Elizabeth Devon Eldridge-Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth Devon Eldridge-Smith has a total of 2 co-authors. Here are the top co-authors by number of shared publications:

  • Lara M. Stepleman

    Department of Psychiatry and Health Behavior, Medical College of Georgia at Augusta University, Augusta, USA

    1 shared publication
  • Megan Loew

    A Department of Psychiatry and Health Behavior , Augusta University - Medical College of Georgia , Augusta , GA , USA

    1 shared publication

Latest Publications

  • The adaptation and validation of a stigma measure for individuals with multiple sclerosis

    by Elizabeth Devon Eldridge-Smith, Megan Loew, Lara M. Stepleman

    Purpose: Stigma negatively impacts quality of life for individuals with multiple sclerosis. Availability of instruments to assess levels of stigma are crucial for monitoring and targeted intervention. The study aims to adapt the Reece Stigma Scale for use with this specific population and examine its reliability and validity. Methods: The scale was administered the 137 participants included in a larger study on identity and multiple sclerosis. Validity was evaluated utilizing the Downing model, as well as assessing potentially related constructs, including adherence, depression, anxiety, quality of life, self-efficacy, and post-traumatic growth. Results: Principal component analysis revealed a one factor solution with excellent internal consistency. Additional construct support offered evidence that higher levels of stigma are related to lower adherence and self-management efficacy, higher levels of anxiety and depressive symptoms, as well as more dissatisfaction with quality of life. Conclusions: This study provides preliminary support for an adapted version of the Reece Stigma Scale, specific to the multiple sclerosis population. The validation data suggests strong psychometric properties. Our findings underscore the clinical importance of measuring and addressing stigma among these patients, with the potential to improve medical (i.e., adherence), psychological (i.e., depression and anxiety), and quality of life outcomes.